Myriam Weyl Ben-Arush

Prof. Myriam Weyl Ben-Arush


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2007 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
Myriam Weyl Ben-ArushMyriam Weyl Ben-Arush
Myriam Weyl Ben-Arush
OIO. Israel
O. Israel
SPS. Postovsky
S. Postovsky
DMD. Militianu
D. Militianu
IMI. Meller
I. Meller
RBR. Bar‐Shalom
R. Bar‐Shalom

1 January 2000 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
Myriam Weyl Ben-ArushMyriam Weyl Ben-Arush
Myriam Weyl Ben-Arush
ISIdo Solt
Ido Solt
ALAbraham Lightman
Abraham Lightman
SLShai Linn
Shai Linn
AKAvraham Kuten
Avraham Kuten
The aim of this study was to investigate the impact of therapy on long-term gonadal function of young people cured of childhood lymphomas and to assess whether a prepubertal state during the treatment protects the gonads from chemotherapy and/or radiotherapy late effects. Clinical evaluation, semen analysis, and endocrine status were studied in 20 survivors of childhood lymphomas. Five patients received Inverted Y radiotherapy, 2320 cGy (1550-4000); all 20 received chemotherapy as follows: MOPP/ABVD protocol, 9 patients; COMP protocol, 5 patients; MOPP protocol, 3 patients; other protocols, 3 patients. Semen analysis results were as follows: normal values, 4/20 patients; oligospermia, 8/20 patients; azoospermia, 8/20 patients; FSH above normal level, 10/20 patients; 4/5 who received Inverted Y irradiation were azoospermic and 1 was severely oligospermic. Treatment damage to the testis involves tubular germinal elements. Radiotherapy and chemotherapy combinations that included nitrogen mustard or cyclophosphamide were associated with high rates of oligospermia and azoospermia. MOPP/ABVD combination did not have a significant better outcome of sperm counts compared to MOPP alone. Age at chemotherapy did not correlate with the sperm count; hence a prepubertal state did not protect the gonad from the late effects of treatment.

1 March 2006 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
Myriam Weyl Ben-ArushMyriam Weyl Ben-Arush
Myriam Weyl Ben-Arush
HGHana Md Geva
Hana Md Geva
RORuth Ofir
Ruth Ofir
TMTania Msc Mashiach
Tania Msc Mashiach
RURachel Uziel
Rachel Uziel
ZDZana Dashkovsky
Zana Dashkovsky
Complementary alternative medicine (CAM) usage and physicians’ attitude was evaluated by interviewing all 100 pediatric cancer patients’ parents and adolescents seen in the last half of 2003 at Meyer Children's Hospital in Israel. Sixty-one percent of the patients used CAM, an average of 3 different treatments per patient. CAM use was higher: among parents having previous CAM experience (85% vs. 51%, P=0.001) and higher education (79% vs. 50%, P=0.024), and in nonreligious families (71% vs. 50%). Jews and Arabs had similar CAM use rates as with different types of therapies. Socioeconomic status does not affect the rate of CAM use (P=0.9) but does affect the type of treatments used: patients of the higher socioeconomic level mainly used chemi-biological remedies and homeopathy (24% and 28% of interviewees; P=0.002). Middle or lower socioeconomic patients mostly used traditional Arab treatments (32% and 54%, respectively; P=0.012). Only 36% discussed it with their physicians, and most discussions were initiated by parents (79%). Beneficial effect was reported by 69% of CAM users. Most interviewees were interested in getting CAM information and availability in the hospital. Most pediatric cancer patients, regardless of their ethnic origin, use CAM without informing their physicians. Physicians should be aware and know more about it, to be advisors for better integrated care.

12 August 2014 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
PDF file
OMOz Mordechai
Oz Mordechai
SPSergey Postovsky
Sergey Postovsky
EVEugene Vlodavsky
Eugene Vlodavsky
AEAyelet Eran
Ayelet Eran
SCShlomi Constantini
Shlomi Constantini
Myriam Weyl Ben-ArushMyriam Weyl Ben-Arush
Myriam Weyl Ben-Arush
Rhabdoid meningioma is an aggressive phenotype of meningioma, associated with a poor prognosis. We present a very rare case of high-grade meningioma with rhabdoid features that eventually expressed in a coma state. Comprehensive genomic profiling using a Next Generation Sequencing (NGS) assay revealed three genomic alterations: activating BRAF mutation (V600E), loss of CDKN2A/2B, and APC I1307K. After treatment with BRAF inhibitor (dabrafenib), the child's clinical condition improved progressively. After seven months, an MEK inhibitor was added (trametinib).

1 July 2006 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
Myriam Weyl Ben-ArushMyriam Weyl Ben-Arush
Myriam Weyl Ben-Arush
RSRachel Bar Shalom
Rachel Bar Shalom
SPSergey Postovsky
Sergey Postovsky
DMDaniela Militianu
Daniela Militianu
Motti HaimiMotti Haimi
Motti Haimi
OIOra Israel
Ora Israel
Alveolar rhabdomyosarcoma (ARS) accounts for 20% to 30% of childhood rhabdomyosarcoma and is known to have a worse prognosis than embryonal rhabdomyosarcoma. Metastatic disease is more frequent in patients with alveolar tumors and these children with metastatic disease fare poorly, with a 5-year survival between 20% and 30%. Therefore, ARS represents a significant diagnostic and therapeutic challenge that requires techniques to provide better assessment of the disease than provided by traditional means. F18 fluorodeoxyglucose-positron emission tomography (FDG-PET) depicts the increased metabolism in abnormal tissues, enabling accurate evaluation of suspicious regional and metastatic disease. The new combined PET/CT systems can further improve PET interpretation and affect patient management. The value of FDG in patients with soft tissue sarcomas has been demonstrated in several series, but none specifically in ARS. This report assesses the use of FDG-PET/CT in the detection of regional and metastatic nodes in 3 children diagnosed with ARS of the extremities. All the 3 patients we present had focally increased tracer uptake in nodal stations on a pretherapy PET performed at diagnosis. Tissue confirmation available in 2 patients was negative in 1 patient and positive for metastatic nodal spread in the other. Metastatic axillary disease was possibly also present in the third patient according to his later course of disease.

1 August 2012 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
RRRon Rabinowicz
Ron Rabinowicz
MBMicha Barchana
Micha Barchana
ILIrena Liphshiz
Irena Liphshiz
BFBoris Msc Futerman
Boris Msc Futerman
SLShai MD Linn
Shai MD Linn
Myriam Weyl Ben-ArushMyriam Weyl Ben-Arush
Myriam Weyl Ben-Arush
Our goal was to describe childhood cancer incidence and survival in Israel and to identify demographic and epidemiologic variations among children and adolescents with cancer. We used data from the Israel National Cancer Registry to examine the incidence and survival of pediatric cancer in Israeli children aged 0 to 19 years, diagnosed during the years 1998 to 2007. Cases were analyzed according to sex, age, ethnicity, and geographic region. Among the 4255 cases of childhood cancer, there was a total age-adjusted incidence rate of 172.4 per million for children aged 0 to 19 years and 153.4 per million for children aged 0 to 14 years. The incidence rate for boys was higher than for girls (192.5 and 153.3, respectively) and higher for Jewish children than for Arab children (177.6 and 156.8, respectively). The largest groups were leukemias (22%), lymphomas (20.2%), and central nervous system tumors (17.4%). The number of new cases increased each year, but the incidence rate remained steady. The survival probability updated to December 2008 was estimated and the 5-year survival was calculated for the new cases until the end of 2003. The overall survival at 5 years was 80.8%, with 72.8% for the Arabic population and 83.2% for the Jewish population, and depended on the diagnosis. Incidence and survival in childhood cancer in Israel is at the same medium level compared with other parts of the world. This study may set the basis for investigating the genetic and environmental factors that cause pediatric cancer in Israel, delineating the genetic basis for ethnic origin disparities in survival.